MSLN and neoplasm: Given the strong preclinical evidence suggestive of the robust anti-tumor activity of anti-mesothelin CAR T-cells, their poor persistence in the TME has hampered their broad clinical applicability in mesothelin-overexpressing tumors; however, research into compensatory measures for these challenges is currently underway, as will be discussed in the following sections.